Contineum Therapeutics (CTNM) Common Equity: 2023-2025
Historic Common Equity for Contineum Therapeutics (CTNM) over the last 2 years, with Sep 2025 value amounting to $180.5 million.
- Contineum Therapeutics' Common Equity fell 14.16% to $180.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $180.5 million, marking a year-over-year decrease of 14.16%. This contributed to the annual value of $198.1 million for FY2024, which is 391.55% up from last year.
- As of Q3 2025, Contineum Therapeutics' Common Equity stood at $180.5 million, which was up 5.30% from $171.4 million recorded in Q2 2025.
- Over the past 5 years, Contineum Therapeutics' Common Equity peaked at $217.5 million during Q2 2024, and registered a low of -$75.6 million during Q1 2024.
- Its 3-year average for Common Equity is $127.4 million, with a median of $182.6 million in 2025.
- Per our database at Business Quant, Contineum Therapeutics' Common Equity surged by 391.55% in 2024 and then decreased by 21.20% in 2025.
- Contineum Therapeutics' Common Equity (Quarterly) stood at -$67.9 million in 2023, then spiked by 391.55% to $198.1 million in 2024, then decreased by 14.16% to $180.5 million in 2025.
- Its Common Equity stands at $180.5 million for Q3 2025, versus $171.4 million for Q2 2025 and $184.8 million for Q1 2025.